Plain-English translation of NCT06056921 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CD19-targeted CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjögren's syndrome, scleroderma, dermatomyositis, and vasculitis. The medication works by taking your own immune cells, engineering them in a lab to fight the cells causing your disease, and putting them back into your body. Early research suggests this approach may help reduce symptoms and allow patients to stop or reduce other medications.
Many patients with autoimmune diseases do not respond well to standard treatments and continue to suffer from serious symptoms. This trial exists to see if this new treatment can help people whose diseases have been difficult to control and to understand whether it is safe.
You likely qualify if…
You likely don't qualify if…
If accepted, you will undergo screening visits to confirm you meet all study criteria, including blood tests and heart/lung function tests. Your doctors will then collect blood cells from you, which will be sent to a lab where they are engineered and grown over several weeks. Once ready, the treated cells will be infused back into your body during a hospital visit. You will then have regular follow-up visits to monitor your response, check for side effects, and measure changes in your disease activity over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Chongqing Precision Biotech Co., Ltd
Enrollment target
~24 participants
Started
August 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liyun Zhang, M.D
Shanxi Bethune Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.